понедельник, 15 февраля 2016 г.

Gilead Has Bottomed - The Question Is How Much Upside Ahead?

Gilead Has Bottomed - The Question Is How Much Upside Ahead?


It has been a frightful six months for biotech investors as the main biotech indices have plunged some 40% from their peaks in July. However, it does appear the some of the big biotech names are in a bottoming phase which is needed before the sector can rally.



from Biotech News